Medicis hands back next-gen botox rights, settles up with Revance

Medicis Pharmaceutical and Revance Therapeutics have come up with a deal to resolve an apparently bitter development dispute. RTT News reports that Revance will get back the rights licensed to Medicis--recently sold to Valeant ($VRX)--on two next-gen botox therapies in exchange for $7 million in cash and $18 million in milestones. Medicis keeps its equity in Revance and the two companies will drop litigation.

The pact clears the way for Revance to push ahead with a late-stage study of RT-001, a treatment for crow's feet and launch a Phase I/II for RT-002. Other elements of the settlement were not disclosed.

Three years ago Medicis ponied up $10 million and promised up to $94 million more to complete a licensing pact on RT-002. Investigators were working on what they believe is a superior delivery technology for the injectable neurotoxin that would level out wrinkles for a longer period of time, making it potentially superior to botox.

Last summer Revance announced that it had raised $45 million in venture cash from Essex Woodlands Health Ventures, NovaQuest Capital, CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corporation. 

- here's the story from RTT News

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.